Non-Narcotic Sleep Medications

First-Line Non-Narcotic Options

The American Academy of Sleep Medicine recommends benzodiazepine receptor agonists (BzRAs) such as eszopiclone, zolpidem, and zaleplon, along with the melatonin receptor agonist ramelteon, as first-line pharmacologic treatments for insomnia—none of these are narcotics (opioids) 1
Eszopiclone (2-3 mg) is effective for both sleep onset and sleep maintenance insomnia, with a longer half-life that improves total sleep time by 28-57 minutes compared to placebo 1, 2
Zolpidem (10 mg) treats both sleep onset and maintenance insomnia, though lower doses (5 mg) are recommended for elderly patients to minimize fall risk 1, 3
Zaleplon (10 mg) has a very short half-life, making it ideal for sleep onset insomnia with minimal next-day residual effects, as it is unlikely to cause morning sedation 1, 4
Ramelteon (8 mg) works on melatonin receptors rather than GABA systems, making it particularly suitable for patients with substance use disorder history since it has no DEA scheduling and no dependence potential 1, 4

Temazepam (15 mg) is an intermediate-acting benzodiazepine for both sleep onset and maintenance, though it carries higher risks of tolerance and dependence compared to Z-drugs 1, 4
Suvorexant (10-20 mg) blocks the orexin pathway that promotes wakefulness, effective for sleep maintenance insomnia with less motor impairment than GABA-acting drugs 1
Doxepin (3-6 mg) works primarily as an H1 histamine antagonist rather than through antidepressant mechanisms, specifically effective for sleep maintenance insomnia with minimal anticholinergic effects 1, 2, 5

The American Academy of Sleep Medicine explicitly recommends against trazodone (50 mg) due to insufficient evidence or unfavorable risk-benefit profiles 1
Diphenhydramine is not recommended due to anticholinergic side effects, particularly problematic in elderly patients 1
Melatonin supplements (2 mg) have insufficient evidence for treating insomnia, though the prescription melatonin agonist ramelteon is effective 1

Symptom pattern determines medication choice, with zaleplon or ramelteon preferred for sleep onset only, and eszopiclone, temazepam, doxepin, or suvorexant for sleep maintenance 1, 4
Elderly patients need lower doses of all sleep medications due to increased sensitivity and fall risk 2, 3
Patients with substance use history should preferentially receive ramelteon (non-scheduled) or suvorexant (lower abuse potential) 3, 4

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be considered first-line treatment before or alongside pharmacotherapy, as it provides sustained improvement without tolerance issues 2, 4, 5
CBT-I includes stimulus control, sleep restriction, relaxation techniques, and cognitive restructuring 5
When medications are used, they should be at the lowest effective dose for the shortest duration, with regular reassessment of continued need 4, 5